

Epratuzumab

Cat. No.:	HY-P99289
CAS No.:	205923-57-5
Target:	CD22
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin's lymphomas (NHL) and certain autoimmune diseases ^[1] .
In Vitro	Epratuzumab binds to CD22 ECD on Biacore with a K_D of 0.7 nM, and resulting CD22 phosphorylation ^[1] . Epratuzumab (0-100 μ M; 1h) results in a dose dependent increase in CD22 internalization in Daudi lymphoma cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Carnahan J, et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3982S-90S.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA